Joanne Kotsopoulos

Dr. Joanne Kotsopoulos

Women’s College Research Institute, Women’s College Hospital, Toronto, Canada; Dalla Lana School of Public Health, University of Toronto, Toronto, Canada.

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 March 2012 in Breast Cancer Research
Verified
Journal Article
Open access
PDF file
Joanne KotsopoulosJoanne Kotsopoulos
Joanne Kotsopoulos
JLJan Lubiński
Jan Lubiński
LSLeonardo Salmena
Leonardo Salmena
HLHenry T Lynch
Henry T Lynch
CKCharmaine Kim-Sing
Charmaine Kim-Sing
TGthe Hereditary Breast Cancer Clinical Study Group
the Hereditary Breast Cancer Clinical Study Group
Introduction: Breastfeeding has been inversely related to breast cancer risk in the general population. Clarifying the role of breastfeeding among women with a BRCA1 or BRCA2 mutation may be helpful for risk assessment and for recommendations regarding prevention. We present an updated analysis of breastfeeding and risk of breast cancer using a large matched sample of BRCA mutation carriers. Methods: We conducted a case-control study of 1,665 pairs of women with a deleterious mutation in either BRCA1 (n = 1,243 pairs) or BRCA2 (n = 422 pairs). Breast cancer cases and unaffected controls were matched on year of birth, mutation status, country of residence and parity. Information about reproductive factors, including breastfeeding for each live birth, was collected from a routinely administered questionnaire. Conditional logistic regression was used to estimate the association between ever having breastfed, as well as total duration of breastfeeding, and the risk of breast cancer. Results: Among BRCA1 mutation carriers, breastfeeding for at least one year was associated with a 32% reduction in risk (OR = 0.68; 95% CI 0.52 to 0.91; P = 0.008); breastfeeding for two or more years conferred a greater reduction in risk (OR = 0.51; 95% CI 0.35 to 0.74). Among BRCA2 mutation carriers, there was no significant association between breastfeeding for at least one year and breast cancer risk (OR = 0.83; 95% CI 0.53 to 1.31; P = 0.43). Conclusions: These data extend our previous findings that breastfeeding protects against BRCA1-, but not BRCA2-associated breast cancer. BRCA mutation carriers should be advised of the benefit of breastfeeding in terms of reducing breast cancer risk.

19 December 2018 in Cancers
Verified
Journal Article
Open access
PDF file
Joanne KotsopoulosJoanne Kotsopoulos
Joanne Kotsopoulos
Women who inherit a deleterious BRCA1 or BRCA2 mutation face substantially increased risks of developing breast cancer, which is estimated at 70%. Although annual screening with magnetic resonance imaging (MRI) and mammography promotes the earlier detection of the disease, the gold standard for the primary prevention of breast cancer remains bilateral mastectomy. In the current paper, I review the evidence regarding the management of healthy BRCA mutation carriers, including key risk factors and protective factors, and also discuss potential chemoprevention options. I also provide an overview of the key findings from the literature published to date, with a focus on data from studies that are well-powered, and preferably prospective in nature.

16 February 2017 in British Journal of Cancer
Verified
Journal Article
Open access
PDF file
SKShana J Kim
Shana J Kim
BRBarry Rosen
Barry Rosen
IFIsabel Fan
Isabel Fan
AIAnna Ivanova
Anna Ivanova
JMJohn R McLaughlin
John R McLaughlin
Joanne KotsopoulosJoanne Kotsopoulos
Joanne Kotsopoulos
Background: Various epidemiologic factors have been shown to influence the risk of ovarian cancer development. Given the high fatality associated with this disease, it is of interest to evaluate the association of prediagnostic hormonal, reproductive, and lifestyle exposures with ovarian cancer-specific survival. Methods: We included 1421 patients with invasive epithelial ovarian cancer diagnosed in Ontario, Canada. Clinical information was obtained from medical records and prediagnostic exposure information was collected by telephone interview. Survival status was determined by linkage to the Ontario Cancer Registry. Proportional hazards regression was used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for ovarian cancer-specific mortality associated with each exposure. Analyses were stratified by histologic subtype to further investigate the associations of risk factors on ovarian cancer-specific mortality. Results: After a mean follow-up of 9.48 years (range 0.59–20.32 years), 655 (46%) women had died of ovarian cancer. Parity (ever) was associated with a significant 29% decreased mortality risk compared with nulliparity (HR=0.71; 95% CI 0.54–0.93; P=0.01). There was a borderline significant association between ever use of oestrogen-containing hormone replacement therapy (HRT) and mortality (HR=0.79; 95% CI 0.62–1.01; P=0.06). A history of cigarette smoking was associated with a significant 25% increased risk of death compared with never smoking (HR=1.25; 95% CI 1.01–1.54; P=0.04). Women with a greater cumulative number of ovulatory cycles had a significantly decreased risk of ovarian cancer-specific death (HR=0.63; 95% CI 0.43–0.94; P=0.02). Increasing BMI (kg m−2) 5 years before diagnosis was associated with an increased risk of death (HR=1.17; 95% CI 1.07–1.28; P=0.0007). Other hormonal or lifestyle factors were not significantly associated with ovarian cancer-specific mortality. Conclusions: Parity, ovulatory cycles, smoking, and BMI may affect survival following the diagnosis of ovarian cancer. Whether or not oestrogen-containing HRT use is beneficial for survival requires further evaluation.

28 October 2020 in Nutrients
Verified
Journal Article
Open access
PDF file
KPKatherine Pullella
Katherine Pullella
Joanne KotsopoulosJoanne Kotsopoulos
Joanne Kotsopoulos
Arsenic is a widespread environmental contaminant and recognized carcinogen for the skin, bladder and lungs. In recent years, there has been an increasing number of studies that have investigated the effects of arsenic exposure and cancer risk at other sites, including the breast. However, to date, the association between arsenic exposure and breast cancer risk remains unclear. This article will provide an overview of arsenic metabolism, the clinically important biomarkers commonly used to assess arsenic exposure, and review the epidemiologic studies examining the role of arsenic exposure on breast cancer risk. Given the large burden of disease associated with breast cancer, it is of the upmost importance to identify risk factors and preventative strategies that could reduce cancer incidence. Limiting exposure to endemic environmental toxins, such as arsenic, represents one such strategy. More studies are required to better ascertain this relationship and to develop the public policy necessary to significantly reduce breast cancer incidence.

1 January 2019 in Gynecologic Oncology
Verified
Journal Article
Closed access
EHElizabeth Hall
Elizabeth Hall
AFAmy Finch
Amy Finch
MJMichelle Jacobson
Michelle Jacobson
BRBarry Rosen
Barry Rosen
KMKelly Metcalfe
Kelly Metcalfe
Joanne KotsopoulosJoanne Kotsopoulos
Joanne Kotsopoulos

21 January 2022 in Cancers
Verified
Journal Article
Open access
PDF file
VGVasily Giannakeas
Vasily Giannakeas
Joanne KotsopoulosJoanne Kotsopoulos
Joanne Kotsopoulos
JBJennifer Brooks
Jennifer Brooks
MCMatthew C. Cheung
Matthew C. Cheung
Laura RosellaLaura Rosella
Laura Rosella
Steven NarodSteven Narod
Steven Narod
Thrombocytosis is associated with cancer progression and death for many cancer types. It is unclear if platelet count is also associated with cancer survival. We conducted a cohort study of 112,231 adults in Ontario with a diagnosis of cancer between January 2007 and December 2016. We included patients who had a complete blood count (CBC) completed in the 30 days prior to their cancer diagnosis. Subjects were assigned to one of three categories according to platelet count: low (≤25th percentile), medium (>25 to <75th percentile), and high (≥75th percentile). Study subjects were followed from the date of their cancer diagnosis for cancer-specific death. Of the 112,231 eligible cancer patients in the cohort study, 40,329 (35.9%) died from their cancer in the follow-up period. Relative to those with a medium platelet count, the rate of cancer-specific death was higher among individuals with a high platelet count (HR 1.52; 95%CI 1.48–1.55) and was lower among individuals with a low platelet count (HR 0.91; 95%CI 0.88–0.93). A high platelet count was associated with poor survival for many cancer types. Platelet count could potentially be used as a risk stratification measure for cancer patients.